Inhibition of pancreatic lipase by berberine and dihydroberberine: an investigation by docking simulation and experimental validation
暂无分享,去创建一个
[1] M. Hudaib,et al. A potential role of Lavandula angustifolia in the management of diabetic dyslipidemia , 2011 .
[2] M. Hudaib,et al. Screening of Some Medicinal Plants for their Pancreatic Lipase Inhibitory Potential , 2011 .
[3] M. Hudaib,et al. Pancreatic lipase inhibition activity of trilactone terpenes of Ginkgo biloba , 2011, Journal of enzyme inhibition and medicinal chemistry.
[4] M. Hudaib,et al. Inhibition of hormone sensitive lipase and pancreatic lipase by Rosmarinus officinalis extract and selected phenolic constituents , 2010 .
[5] P. R. Vuddanda,et al. Berberine: a potential phytochemical with multispectrum therapeutic activities , 2010, Expert opinion on investigational drugs.
[6] G. Davies,et al. Berberine inhibits adipogenesis in high-fat diet-induced obesity mice. , 2010, Fitoterapia.
[7] M. Lane,et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. , 2009, American journal of physiology. Endocrinology and metabolism.
[8] S. Panigrahi,et al. Obesity: pathophysiology and clinical management. , 2009, Current medicinal chemistry.
[9] Jayaraman Chandrasekhar,et al. Strategies and tactics for optimizing the Hit-to-Lead process and beyond--a computational chemistry perspective. , 2008, Drug discovery today.
[10] K. Bhutani,et al. Pancreatic lipase inhibitors from natural sources: unexplored potential. , 2007, Drug Discovery Today.
[11] Y. Aggoun,et al. Obesity, Metabolic Syndrome, and Cardiovascular Disease , 2007, Pediatric Research.
[12] Dunstan Cooke,et al. The obesity pipeline: current strategies in the development of anti-obesity drugs , 2006, Nature Reviews Drug Discovery.
[13] D. James,et al. Berberine, a Natural Plant Product, Activates AMP-Activated Protein Kinase With Beneficial Metabolic Effects in Diabetic and Insulin-Resistant States , 2006, Diabetes.
[14] D. Cummings,et al. Emerging therapeutic strategies for obesity. , 2006, Endocrine reviews.
[15] J. Halford. Obesity drugs in clinical development. , 2006, Current opinion in investigational drugs.
[16] Mutasem O. Taha,et al. Berberine potently inhibits protein tyrosine phosphatase 1B: Investigation by docking simulation and experimental validation , 2006, Journal of enzyme inhibition and medicinal chemistry.
[17] E. Cairns. Obesity: the fat lady sings? , 2005, Drug discovery today.
[18] Satoru Inaba,et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins , 2004, Nature Medicine.
[19] C. Arbeeny. Addressing the unmet medical need for safe and effective weight loss therapies. , 2004, Obesity research.
[20] Yuguang Shi,et al. Lipid metabolic enzymes: emerging drug targets for the treatment of obesity , 2004, Nature Reviews Drug Discovery.
[21] M. Mukherjee. Human digestive and metabolic lipases—a brief review , 2003 .
[22] K. Hofbauer. Molecular pathways to obesity , 2002, International Journal of Obesity.
[23] W. Weiss. Pharmacotherapy for obesity. , 2002, The New England journal of medicine.
[24] S. Peikin,et al. Orlistat: its current status as an anti-obesity drug. , 2002, European journal of pharmacology.
[25] George A. Bray,et al. Medicinal strategies in the treatment of obesity , 2000, Nature.
[26] L. Sjöström,et al. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.
[27] H. van Tilbeurgh,et al. The 2.46 A resolution structure of the pancreatic lipase-colipase complex inhibited by a C11 alkyl phosphonate. , 1994, Biochemistry.
[28] H. Tilbeurgh,et al. Structure of the pancreatic lipase–procolipase complex , 1992, Nature.
[29] F. Winkler,et al. Structure of human pancreatic lipase , 1990, Nature.